These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16422019)

  • 1. Antipsychotic drugs and schizophrenia.
    Duan N; Kraemer HC; Mintz J
    N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16422019
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine and weight gain.
    Isaac MB; Isaac MT
    Am J Psychiatry; 2005 Sep; 162(9):1764-5; author reply 1765. PubMed ID: 16135655
    [No Abstract]   [Full Text] [Related]  

  • 3. Is olanzapine a brain-sparing medication?
    Joober R; Schmitz N; Malla A; Sengupta S; Karma S
    Arch Gen Psychiatry; 2006 Nov; 63(11):1292. PubMed ID: 17088510
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term treatment with atypical antipsychotics and risk of weight gain.
    Stip E; Anselmo K; Wolfe M; Lessard C; Landry P
    Drug Saf; 2006; 29(6):550-2; author reply 552. PubMed ID: 16752937
    [No Abstract]   [Full Text] [Related]  

  • 5. Bofu-tsusho-san effectively attenuates the weight gain observed after receiving olanzapine.
    Yamamoto N; Inada T
    Psychiatry Clin Neurosci; 2008 Dec; 62(6):747. PubMed ID: 19068015
    [No Abstract]   [Full Text] [Related]  

  • 6. Unusual suspect for antipsychotic-induced diabetes.
    O'Neill MF
    Drug Discov Today; 2005 Oct; 10(20):1338. PubMed ID: 16253867
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.
    Godlewska BR; Olajossy-Hilkesberger L; Olajossy M; Limon J; Landowski J
    J Clin Psychopharmacol; 2013 Jun; 33(3):436-7. PubMed ID: 23609395
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.
    Markham-Abedi C; de Leon J
    J Clin Psychiatry; 2006 Sep; 67(9):1473-4. PubMed ID: 17017841
    [No Abstract]   [Full Text] [Related]  

  • 13. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.
    Karagianis J; Hoffmann VP; Arranz B; Treuer T; Maguire GA; de Haan L; Chawla B
    Hum Psychopharmacol; 2008 Jun; 23(4):275-81. PubMed ID: 18338426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
    Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D
    Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751
    [No Abstract]   [Full Text] [Related]  

  • 15. The effectiveness criterion: balancing efficacy against the risks of weight gain.
    Citrome L
    J Clin Psychiatry; 2007; 68 Suppl 12():12-7. PubMed ID: 17956151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.
    Lin YH; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):613-5. PubMed ID: 16194268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
    Koga M; Nakayama K
    Acta Psychiatr Scand; 2005 Jul; 112(1):75-6; discussion 77. PubMed ID: 15952949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of antipsychotic-induced weight gain.
    Fraguas D; Kirchoff D
    Med Sci Monit; 2006 May; 12(5):LE6-7. PubMed ID: 16641884
    [No Abstract]   [Full Text] [Related]  

  • 20. The choice of antipsychotic drugs for schizophrenia.
    Freedman R
    N Engl J Med; 2005 Sep; 353(12):1286-8. PubMed ID: 16172204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.